Valneva's Lyme Vaccine Enters EMA Review — But the Rally Is Running on Regulatory Hope, Not Fundamentals
Published on 08/17/2026 at 18:11 | Redaktion boerse-global.de
The French biotech's stock has been on a tear since European regulators formally accepted its Lyme disease vaccine application for review, yet the euphoria sits awkwardly alongside a half-year report that shows losses widening and cash reserves shrinking.
Shares closed Friday at €3.06 after jumping 27% on the day, extending a weekly gain of 31% and a 30-day advance of 43%. The move came after the European Medicines Agency validated the marketing authorization application for PF-07307405, the six-valent Lyme disease vaccine candidate developed in partnership with Pfizer. The stock now trades roughly 34% above its 50-day moving average, and with a relative strength index of 80.6, it is technically in overbought territory. Thirty-day volatility stands at 88%.
A Regulatory Milestone With a Caveat
The EMA's validation kicks off the formal review process for the vaccine, which is based on the OspA surface protein and targets six strains of Borrelia. The submission draws on data from the Phase 3 VALOR trial, which enrolled 9,437 participants and demonstrated efficacy above 70% with a favorable safety profile — though the primary analysis missed the statistical significance threshold due to lower-than-expected case counts.
Under the partnership struck in 2020, Pfizer holds exclusive commercialization rights. Should the vaccine win approval, Valneva stands to collect milestone payments of up to $143 million, plus tiered royalties ranging from 14% to 22% on future sales.
The regulatory progress has captured Wall Street's attention. TD Cowen initiated coverage on August 11 with a Buy rating and a $12 price target, citing a de-risked partnership profile with Pfizer and projected peak sales of €3.1 billion by 2035. The firm also pointed to Valneva's diversified vaccine portfolio as a supporting factor.
Should investors sell immediately? Or is it worth buying Valneva?
The Numbers Behind the Narrative
The same Friday that brought the EMA news also brought Valneva's first-half results — and they make for a starker read. Total revenue fell to €65.8 million from €97.6 million in the year-earlier period, while product sales came in at €64.0 million. The operating loss reached €49.9 million, and the net loss widened to €63.3 million against €20.8 million a year earlier.
Management reaffirmed its full-year guidance nonetheless, sticking with product sales of €135 million to €150 million and total revenue of €145 million to €160 million. Analysts have since nudged their 2026 revenue estimate to €151.1 million.
To slow the cash burn, Valneva has rolled out a global restructuring program involving significant job cuts, a reprioritization of research activities, and streamlined operations worldwide. The company also agreed to sell its production site in Nantes for €6.2 million to Nantes Métropole, with the transaction expected to close in September 2026. Cash stood at €121.5 million as of June 30, bolstered by the final proceeds of a recently completed €84 million capital raise.
Pipeline Signals Beyond Lyme
Investors have additional catalysts to track in the coming months. Valneva is due to report results from the Phase 2 safety and immunogenicity study S4V2 in infants, as well as a Phase 2b human challenge study, during the third quarter of 2026.
In the chikungunya franchise, a locally produced version of the VLA1555 vaccine, marketed as "Butantan-chik," received approval in Brazil in May. A pilot vaccination campaign with the Instituto Butantan has so far reached roughly 50,000 adults aged 18 to 59.
A Rally Priced on Approval Odds
The average analyst price target has been raised 19% to €5.23, even as consensus expects a larger reported loss this year. That divergence underscores how much of the current valuation hinges on the Lyme vaccine's approval prospects rather than the underlying business trajectory.
The stock remains 43% below its August high of €5.36, a reminder of how far it has fallen — and how much ground a successful EMA review would need to reclaim. Whether the regulatory momentum can outrun the financial drag of restructuring and mounting losses is the question now hanging over Valneva's shareholders.
Ad
Valneva Stock: New Analysis - 17 August
Fresh Valneva information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
